Intrauterine Devices Market By Product Type (Hormonal Intrauterine Device and Copper Intrauterine Device), By Material (Plastic, Copper and Hormonal (Levonorgestrel)), By Age Group (15-24 years, 25-34 years, 35-44 years and Above 44 years), By End-user (Hospital, Gynecology Clinics, Community Health Care Centers and Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Intrauterine Devices market accounted for USD 6.35 Billion in 2024 and is expected to reach USD 9.62 Billion by 2035, growing at a CAGR of around 3.85% between 2025 and 2035. The intrauterine devices market is that specific section in the health care industry focusing on the production, manufacture, and distribution of IUDs, which are small, T-shaped devices inserted into the uterus for long-term contraception. There are essentially two types of IUDs; namely, hormonal IUDs which emit hormones to prevent pregnancy, and copper IUDs, which with the help of copper give a lethal environment for the sperm. Increasing consciousness about reproductive health, an ever-increasing interest in long-acting reversible contraceptives, and government efforts at promoting family planning have all contributed to huge growth in the market. Advances in the product technology and the emergence of Eco-friendly products also contribute towards innovation in this market.

Report Scope:

Market Dynamics

Government Endorsement Boosting Contraceptive Access and Market Potential

Supportive government policies and programs encourage family planning through the use of contraceptives for improved reproductive health. For instance, comprehensive sex education, free availability of services to acquire contraceptives, and funds to support family planning clinics must be available. For the bulk of the population, governments can subsidize the costs of access of such contraceptive use, thereby making these resources relatively cheaper for lower-income populations. Public awareness campaigns may also help remove social stigmas attached to contraceptive use and therefore inform the citizenry on what is necessary for them.

For instance, in 2021, the U.S. Department of Health and Human Services reiterated that all FDA-approved contraception, including most IUD options, must be covered by insurers without cost-sharing. As research by the Guttmacher Institute has noted, expanded access to low-cost contraception contributed considerably to the high levels of IUD use among women under 30 and low-income women. Such measures not only empower individuals to make informed choices but also contribute to better health outcomes, reduced unintended pregnancies, and improved socio-economic conditions. Moreover, through the enhancement and advancement of rights related to reproductive health, governments can indeed promote gender equality and general welfare in their communities.

Rising Preference for Long-Term Contraceptive Solutions Fuels Market Growth

That shift in preference to the use of more long-term methods of contraception, such as IUDs, signifies that there is a change in choice when it comes to reproductive health. Increasingly, individuals and couples look for safety and low maintenance techniques that minimize such decisions and management involving frequent methods like pill or condom use. This has been possible with IUDs-they are a very effective means of contraception for a couple of years, keeping within the preference for most to plan their families with minimal disruption.

The research shows the increase in user satisfaction due to long-acting reversible contraceptives (LARCs) having effectiveness above that of short-term methods for the prevention of unintended pregnancies. Moreover, government initiatives and campaigns enhancing awareness regarding IUD and its benefits have portrayed this as a trend. With higher recognition of the advantages of long-term contraceptive options, healthcare providers have started recommending IUDs as a favored preference, hence increasing its accessibility and acceptance across various strata.

Misinformation about IUD Safety and Effectiveness Hinders Market Growth

Several of the biggest myths encountered in the adoption of IUDs include their safety and effectiveness. Many believe that the IUD causes infertility or has a myriad of side effects, something that research shows to be otherwise, safe for most users. Most of these beliefs arise through lack of proper sex education or other cultural beliefs that limit the adoption of the IUDs among potential users.

Women, therefore, would make short-term, less effective types of contraception, with resulting unwanted pregnancies. Such a flawed perception will be corrected only through focused education and outreach programs for women to become more accepting and using IUDs extensively.

Innovative IUDs with Hormonal Benefits Present New Market Opportunities

Development of intrauterine devices releasing hormones that will help regulate the menstrual cycle is a gigantic opportunity in the market. Hormonal IUDs will therefore be capable of assisting and managing heavy menstrual bleeding thus reducing dysmenorrhea, which generally presents a common problem for many females. According to the National Institutes of Health (NIH), Compared to the various other medications and hormonal treatments, hormonal IUDs are the most effective at reducing bleeding and the related problems. The levonorgestrel intrauterine system reduces blood loss by up to 86 percent after three months, and by up to 97 percent after 12 months.

In addition, with the healthcare approach moving progressively towards a holistic perspective on women's health, advances in IUDs that consider factors for contraception and menstruation will enhance its uptake. Coming initiatives, be it government in terms of improving women's health or research-based and development-oriented to come up with more effective and comprehensive solutions on contraceptive methods, will rise for the growing importance of this area.

Eco-Conscious IUDs Leveraging Sustainable Materials for Market Growth

The IUD market provides a prospect to emphasize the use of environmental material inputs and processes of production. Eco-friendly raw materials which can be biodegradable polymers or recycled components reduce ecological burden while catering to the demands of the ecologically concerned consumer. Sustainable production can help minimize waste and energy use in a fast-growing environment concerned with global trends toward sustainability.

Since the consumer is becoming more sensitive to environmental issues, that would be an impetus for differentiation and growth in the market into broader public health and ecological objectives. Eco-friendly IUDs should be developed with the use of biodegradable materials such as poly(lactic acid) or plant-based polymers. Education campaigns on this would create the companies with a loyal customer base among the population of eco-conscious customers.

Industry Experts Opinion

“The FP2020 partnership has bent the curve of progress sharply upward and responded with strength to Covid-19. As a result of coordinated partnership over the past eight years, millions of women and girls can now plan their own futures through access to life-changing, and lifesaving, contraceptives. This momentum must be accelerated as the family planning community plans for the future.”

•  Beth Schlachter, Executive Director of FP2020

“We are thrilled by the overwhelming response from both our existing and new investors who share our determination and dedication to improving therapies for women, starting with our advanced IUD and integrated system for insertion and retrieval. Notably, this oversubscribed round supports our preclinical development through an IND filing in early 2025, a major milestone in our development timeline.”

• Mary Beth Cicero, CEO of 3Daughters

Segment Analysis

Based on the product type, the market of Intrauterine Devices has been classified into hormonal intrauterine device and copper intrauterine device. Hormonal intrauterine devices are expected to have the greatest market share primarily for the reason that they provide two advantages such as the protection of effective contraception and alleviation of menstrual symptoms including heavy flow and cramping. Their duration of action is usually long-lived, that is, 3 to 7 years. The convenience provided is an added advantage. More education and better acceptance of hormonal contraceptive methods also help in surging popularity of these IUDs over the copper ones.

Based on the age group, the market of Intrauterine Devices has been classified into 15-24 years, 25-34 years, 35-44 years and Above 44 years. The age group of 25-34 is usually typically leads in IUD usage, since people in this age category prefer safer and longer-lasting methods of contraception. They tend to be better informed than others about different contraceptive methods and most prefer methods that are more convenient and effective, so hormonal IUDs come as a particularly appealing supplement to their repertoires because they minimize menstrual symptoms.

Regional Analysis

In North America, there is a surge in the Intrauterine Devices market due to strong emphasis on reproductive health and family planning. The United States has greater market share in the country mainly because of strong consumer awareness and acceptance of various types of contraceptive options available, including both hormonal as well as copper IUDs. Insurance coverage for IUDs has been made progressively more comprehensive in recent years, hence making the product available for a larger section of the population. More healthcare providers prescribe LARCs because they are very effective and convenient. Huge educational campaigns on reproductive health and family planning can provide a good backbone for support towards market growth. There are also established prominent manufacturers of these devices as well as continuous innovation in the kind of products that enter the market which characterizes this dynamic landscape.

The Asia-Pacific regional landscape for the intrauterine devices market is highly dynamic, thereby providing increasing awareness and acceptance towards reproductive health solutions. India and China lead the charge in growth, as large populations and the emergence of a middle class seek effective contraceptive methods. Increasing educational efforts around reproductive health boost the demand for long-acting reversible contraceptives, especially hormonal IUDs. The market expands due to factors such as urbanization and shifting social attitudes toward family planning.

Competitive Landscape

Intrauterine devices market landscape is the competition where innovative and evolving market players coexist with the established pharmaceutical companies. Established players, including Bayer, Merck, and CooperSurgical, majorly hold the IUD market with their strong portfolio of hormonal and copper IUDs. Competition in this market is mainly driven by product efficacy, safety, and the development of advanced features, such as eco-friendly materials and longer-lasting options. Regulatory approvals and clinical studies can be seen as major factors shaping the competitive approach. Increasing demand for certain contraceptive solutions may prove companies to be aggressive at partnership and mergers for effective market position.

Intrauterine Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, CooperSurgical, a leading global developer of women's healthcare products, announced launch of a new inserter designed for single-hand placement of Paragard® which was recently approved by the U.S. Food and Drug Administration (FDA).
• In January 2024, Medicines360, a global nonprofit dedicated to women's health, collaborated with DKT WomanCare, a global distributor of contraceptive products, to increase availability of AVIBELA, the only cost-effective, high-quality hormonal IUD with over 99% effectiveness. This partnership aims to enhance awareness and accessibility and usage of the highly effective contraceptive option.

Report Coverage:

By Product Type

• Hormonal Intrauterine Device
• Copper Intrauterine Device

By Material                  

• Plastic
• Copper
• Hormonal (Levonorgestrel)

By Age Group

• 15-24 years
• 25-34 years
• 35-44 years
• Above 44 years

End-user  

• Hospital
• Gynecology Clinics
• Community Health Care Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Bayer AG
• CooperSurgical, Inc.
• Merck & Co., Inc.
• Teleflex Incorporated
• Hologic, Inc.
• TOLMAR Pharmaceuticals, Inc.
• Nusil Age Group  LLC
• Medicraft Limited
• Ethypharm
• Ferring Pharmaceuticals
• VivaSight
• HLL Lifecare Limited
• Suhar International
• Screaming Eagle, LLC
• AstraZeneca PLC

Frequently Asked Questions (FAQs)